| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nitric Oxide | 29 | 2022 | 173 | 3.590 |
Why?
|
| Seizures | 22 | 2023 | 141 | 2.540 |
Why?
|
| Muscle Relaxation | 10 | 2014 | 32 | 2.020 |
Why?
|
| Anticonvulsants | 15 | 2022 | 104 | 1.680 |
Why?
|
| Lithium Chloride | 10 | 2012 | 11 | 1.590 |
Why?
|
| Penis | 7 | 2012 | 29 | 1.420 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 6 | 2017 | 87 | 1.320 |
Why?
|
| Pentylenetetrazole | 21 | 2022 | 21 | 1.320 |
Why?
|
| Dose-Response Relationship, Drug | 33 | 2022 | 860 | 1.250 |
Why?
|
| Lithium | 6 | 2022 | 20 | 1.120 |
Why?
|
| Muscular Dystrophy, Oculopharyngeal | 1 | 2025 | 3 | 0.970 |
Why?
|
| Antidepressive Agents | 6 | 2017 | 225 | 0.960 |
Why?
|
| Myotonic Dystrophy | 1 | 2025 | 13 | 0.950 |
Why?
|
| Muscular Dystrophy, Facioscapulohumeral | 1 | 2025 | 44 | 0.920 |
Why?
|
| Diabetes Mellitus, Experimental | 4 | 2009 | 198 | 0.890 |
Why?
|
| Excitatory Amino Acid Antagonists | 4 | 2015 | 36 | 0.880 |
Why?
|
| Swimming | 5 | 2017 | 27 | 0.850 |
Why?
|
| NG-Nitroarginine Methyl Ester | 21 | 2022 | 29 | 0.850 |
Why?
|
| Antimanic Agents | 4 | 2012 | 31 | 0.820 |
Why?
|
| Morphine | 7 | 2021 | 58 | 0.730 |
Why?
|
| Rats | 24 | 2024 | 1976 | 0.720 |
Why?
|
| Arachidonic Acids | 5 | 2009 | 27 | 0.710 |
Why?
|
| Animals | 61 | 2024 | 20530 | 0.710 |
Why?
|
| Rats, Sprague-Dawley | 18 | 2020 | 620 | 0.640 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2024 | 507 | 0.610 |
Why?
|
| Male | 54 | 2025 | 29366 | 0.590 |
Why?
|
| Sumatriptan | 4 | 2022 | 5 | 0.580 |
Why?
|
| Polyunsaturated Alkamides | 2 | 2007 | 5 | 0.550 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 106 | 0.520 |
Why?
|
| Spinal Cord Injuries | 3 | 2021 | 48 | 0.520 |
Why?
|
| Analysis of Variance | 12 | 2016 | 608 | 0.500 |
Why?
|
| Disease Models, Animal | 23 | 2022 | 2165 | 0.490 |
Why?
|
| Cannabinoid Receptor Modulators | 4 | 2007 | 8 | 0.490 |
Why?
|
| KATP Channels | 2 | 2016 | 3 | 0.470 |
Why?
|
| Neoplasms | 1 | 2025 | 1344 | 0.460 |
Why?
|
| Behavior, Animal | 5 | 2012 | 228 | 0.460 |
Why?
|
| Ketamine | 2 | 2017 | 37 | 0.450 |
Why?
|
| Mitochondria | 1 | 2018 | 366 | 0.450 |
Why?
|
| Enzyme Inhibitors | 14 | 2020 | 372 | 0.450 |
Why?
|
| Stomach | 1 | 2014 | 85 | 0.440 |
Why?
|
| Electroconvulsive Therapy | 1 | 2013 | 15 | 0.440 |
Why?
|
| Mice | 32 | 2022 | 10768 | 0.440 |
Why?
|
| Cromakalim | 4 | 2016 | 4 | 0.420 |
Why?
|
| Arginine | 10 | 2011 | 122 | 0.400 |
Why?
|
| Nitroprusside | 7 | 2014 | 14 | 0.390 |
Why?
|
| Drug Tolerance | 3 | 2010 | 33 | 0.390 |
Why?
|
| Hydrogen Sulfide | 1 | 2012 | 9 | 0.380 |
Why?
|
| Freezing Reaction, Cataleptic | 2 | 2009 | 3 | 0.380 |
Why?
|
| Pilocarpine | 2 | 2022 | 5 | 0.370 |
Why?
|
| Status Epilepticus | 2 | 2022 | 23 | 0.360 |
Why?
|
| Neuralgia | 2 | 2021 | 22 | 0.360 |
Why?
|
| Time Factors | 8 | 2024 | 3737 | 0.360 |
Why?
|
| Depressive Disorder, Major | 1 | 2013 | 254 | 0.360 |
Why?
|
| Impotence, Vasculogenic | 2 | 2007 | 3 | 0.350 |
Why?
|
| Tumor Necrosis Factor-alpha | 6 | 2024 | 612 | 0.350 |
Why?
|
| Narcotic Antagonists | 6 | 2022 | 135 | 0.340 |
Why?
|
| Muscle, Smooth | 2 | 2008 | 134 | 0.340 |
Why?
|
| Calcium Channel Blockers | 1 | 2010 | 60 | 0.330 |
Why?
|
| Piperidines | 9 | 2022 | 63 | 0.320 |
Why?
|
| Paroxetine | 1 | 2009 | 16 | 0.320 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2009 | 30 | 0.320 |
Why?
|
| Cholestasis | 4 | 2010 | 58 | 0.300 |
Why?
|
| Gastric Fundus | 1 | 2007 | 2 | 0.280 |
Why?
|
| Lithium Compounds | 1 | 2007 | 8 | 0.280 |
Why?
|
| Anti-Inflammatory Agents | 4 | 2024 | 173 | 0.280 |
Why?
|
| Erectile Dysfunction | 2 | 2022 | 26 | 0.280 |
Why?
|
| Analgesics, Opioid | 5 | 2020 | 532 | 0.280 |
Why?
|
| In Vitro Techniques | 6 | 2012 | 486 | 0.270 |
Why?
|
| Receptors, Cholinergic | 1 | 2006 | 20 | 0.260 |
Why?
|
| Glyburide | 5 | 2022 | 9 | 0.250 |
Why?
|
| Drug Interactions | 7 | 2011 | 127 | 0.250 |
Why?
|
| Naltrexone | 5 | 2022 | 89 | 0.240 |
Why?
|
| Penile Erection | 3 | 2012 | 7 | 0.230 |
Why?
|
| Receptor, Cannabinoid, CB1 | 4 | 2009 | 15 | 0.230 |
Why?
|
| Neuroprotective Agents | 2 | 2022 | 75 | 0.230 |
Why?
|
| Depression | 2 | 2012 | 883 | 0.230 |
Why?
|
| Electric Stimulation | 5 | 2014 | 140 | 0.230 |
Why?
|
| Opioid Peptides | 3 | 2011 | 4 | 0.230 |
Why?
|
| Cannabinoid Receptor Antagonists | 2 | 2018 | 4 | 0.220 |
Why?
|
| Exploratory Behavior | 3 | 2009 | 36 | 0.220 |
Why?
|
| Convulsants | 4 | 2018 | 7 | 0.220 |
Why?
|
| Delayed Diagnosis | 1 | 2024 | 45 | 0.220 |
Why?
|
| Humans | 15 | 2025 | 62455 | 0.220 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2024 | 28 | 0.220 |
Why?
|
| Retrospective Studies | 3 | 2025 | 6484 | 0.220 |
Why?
|
| Paclitaxel | 1 | 2024 | 100 | 0.210 |
Why?
|
| Genetic Testing | 1 | 2024 | 131 | 0.210 |
Why?
|
| Gastrointestinal Diseases | 1 | 2024 | 70 | 0.210 |
Why?
|
| Cannabinoids | 3 | 2008 | 41 | 0.200 |
Why?
|
| Drug Synergism | 7 | 2011 | 142 | 0.200 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2023 | 100 | 0.190 |
Why?
|
| Sleep Wake Disorders | 1 | 2023 | 69 | 0.190 |
Why?
|
| Oxidative Stress | 3 | 2024 | 293 | 0.190 |
Why?
|
| Epilepsy | 1 | 2023 | 110 | 0.190 |
Why?
|
| Liver Cirrhosis, Biliary | 2 | 2014 | 5 | 0.190 |
Why?
|
| Azithromycin | 1 | 2021 | 31 | 0.190 |
Why?
|
| Aged | 3 | 2025 | 14203 | 0.190 |
Why?
|
| Potassium Channels | 3 | 2022 | 58 | 0.190 |
Why?
|
| Electroshock | 2 | 2018 | 5 | 0.180 |
Why?
|
| Neurodegenerative Diseases | 1 | 2023 | 139 | 0.180 |
Why?
|
| Nicotine | 2 | 2015 | 116 | 0.180 |
Why?
|
| Agmatine | 2 | 2011 | 3 | 0.180 |
Why?
|
| Migraine Disorders | 1 | 2021 | 41 | 0.180 |
Why?
|
| Receptors, Serotonin, 5-HT3 | 2 | 2011 | 4 | 0.170 |
Why?
|
| Receptor, Serotonin, 5-HT1D | 1 | 2020 | 1 | 0.170 |
Why?
|
| Receptor, Serotonin, 5-HT1B | 1 | 2020 | 2 | 0.170 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2021 | 104 | 0.170 |
Why?
|
| Pyrazoles | 6 | 2018 | 78 | 0.170 |
Why?
|
| Adult | 3 | 2025 | 16564 | 0.170 |
Why?
|
| Ovariectomy | 3 | 2012 | 101 | 0.170 |
Why?
|
| Endothelium | 3 | 2011 | 21 | 0.170 |
Why?
|
| Middle Aged | 3 | 2025 | 17293 | 0.170 |
Why?
|
| Pyridines | 2 | 2022 | 111 | 0.170 |
Why?
|
| Young Adult | 2 | 2025 | 4607 | 0.170 |
Why?
|
| Sulfones | 2 | 2011 | 38 | 0.170 |
Why?
|
| Thalidomide | 1 | 2020 | 34 | 0.170 |
Why?
|
| Ischemic Preconditioning | 2 | 2012 | 8 | 0.170 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2021 | 164 | 0.160 |
Why?
|
| Piperazines | 2 | 2011 | 76 | 0.160 |
Why?
|
| Surgical Flaps | 3 | 2010 | 117 | 0.160 |
Why?
|
| Locomotion | 1 | 2020 | 116 | 0.160 |
Why?
|
| Nitric Oxide Synthase | 7 | 2020 | 47 | 0.160 |
Why?
|
| Hyperalgesia | 3 | 2024 | 15 | 0.160 |
Why?
|
| Analgesics | 3 | 2021 | 102 | 0.150 |
Why?
|
| Tacrolimus | 2 | 2009 | 65 | 0.150 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 2529 | 0.150 |
Why?
|
| Female | 7 | 2025 | 32375 | 0.140 |
Why?
|
| Disease Susceptibility | 2 | 2009 | 166 | 0.140 |
Why?
|
| Motor Activity | 3 | 2012 | 343 | 0.140 |
Why?
|
| Tramadol | 1 | 2017 | 16 | 0.140 |
Why?
|
| Signal Transduction | 4 | 2012 | 3016 | 0.140 |
Why?
|
| Citalopram | 2 | 2021 | 21 | 0.140 |
Why?
|
| Endocannabinoids | 2 | 2007 | 22 | 0.130 |
Why?
|
| Pandemics | 1 | 2021 | 661 | 0.130 |
Why?
|
| Lung | 1 | 2021 | 937 | 0.130 |
Why?
|
| Triamterene | 1 | 2016 | 1 | 0.130 |
Why?
|
| Mental Disorders | 1 | 2023 | 755 | 0.130 |
Why?
|
| Immunosuppressive Agents | 2 | 2009 | 376 | 0.130 |
Why?
|
| TRPV Cation Channels | 2 | 2024 | 20 | 0.120 |
Why?
|
| Estradiol | 3 | 2012 | 257 | 0.120 |
Why?
|
| Hindlimb Suspension | 1 | 2015 | 3 | 0.120 |
Why?
|
| Spinal Cord | 3 | 2021 | 204 | 0.120 |
Why?
|
| Receptors, Opioid | 2 | 2022 | 16 | 0.120 |
Why?
|
| Dizocilpine Maleate | 2 | 2017 | 9 | 0.120 |
Why?
|
| Antioxidants | 2 | 2024 | 251 | 0.120 |
Why?
|
| Depressive Disorder | 1 | 2017 | 285 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 783 | 0.110 |
Why?
|
| Apoptosis | 2 | 2010 | 1065 | 0.110 |
Why?
|
| Stress, Psychological | 1 | 2018 | 469 | 0.110 |
Why?
|
| Indomethacin | 3 | 2012 | 22 | 0.110 |
Why?
|
| Acetylcholine | 2 | 2011 | 44 | 0.110 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2013 | 120 | 0.110 |
Why?
|
| Adenosine Triphosphate | 2 | 2022 | 292 | 0.100 |
Why?
|
| Stroke | 1 | 2022 | 1184 | 0.100 |
Why?
|
| Cyclic GMP | 1 | 2012 | 30 | 0.100 |
Why?
|
| Drug Combinations | 2 | 2009 | 151 | 0.100 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2013 | 391 | 0.100 |
Why?
|
| Cystathionine gamma-Lyase | 1 | 2012 | 1 | 0.100 |
Why?
|
| Cystathionine beta-Synthase | 1 | 2012 | 4 | 0.100 |
Why?
|
| Nitrogen Oxides | 1 | 2012 | 11 | 0.100 |
Why?
|
| Alkynes | 1 | 2012 | 24 | 0.100 |
Why?
|
| Nitrites | 2 | 2009 | 11 | 0.090 |
Why?
|
| Glycine | 1 | 2012 | 49 | 0.090 |
Why?
|
| Nitrates | 2 | 2009 | 22 | 0.090 |
Why?
|
| Cannabinoid Receptor Agonists | 2 | 2008 | 8 | 0.090 |
Why?
|
| Reperfusion Injury | 1 | 2012 | 53 | 0.090 |
Why?
|
| Morphinans | 1 | 2011 | 2 | 0.090 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 2011 | 21 | 0.090 |
Why?
|
| Guinea Pigs | 1 | 2011 | 84 | 0.090 |
Why?
|
| Oxadiazoles | 2 | 2008 | 8 | 0.090 |
Why?
|
| Magnesium Chloride | 1 | 2010 | 6 | 0.090 |
Why?
|
| Rats, Wistar | 2 | 2021 | 185 | 0.090 |
Why?
|
| Quinoxalines | 2 | 2008 | 37 | 0.090 |
Why?
|
| Estrogens | 2 | 2008 | 115 | 0.090 |
Why?
|
| Lithium Carbonate | 1 | 2010 | 12 | 0.090 |
Why?
|
| Hypoglycemic Agents | 2 | 2009 | 214 | 0.080 |
Why?
|
| Vasodilation | 1 | 2010 | 36 | 0.080 |
Why?
|
| Parasympatholytics | 1 | 2009 | 7 | 0.080 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2008 | 45 | 0.080 |
Why?
|
| Blood Glucose | 2 | 2009 | 484 | 0.080 |
Why?
|
| Potassium Channel Blockers | 2 | 2022 | 27 | 0.080 |
Why?
|
| Immobility Response, Tonic | 1 | 2009 | 2 | 0.080 |
Why?
|
| Vasodilator Agents | 2 | 2008 | 67 | 0.080 |
Why?
|
| Endothelium, Vascular | 1 | 2010 | 175 | 0.080 |
Why?
|
| Muscle, Skeletal | 1 | 2014 | 729 | 0.080 |
Why?
|
| Morphine Dependence | 1 | 2008 | 1 | 0.080 |
Why?
|
| Myocytes, Cardiac | 1 | 2009 | 96 | 0.080 |
Why?
|
| Malondialdehyde | 2 | 2024 | 15 | 0.080 |
Why?
|
| Nitrergic Neurons | 1 | 2008 | 1 | 0.080 |
Why?
|
| Orchiectomy | 1 | 2008 | 31 | 0.080 |
Why?
|
| Dithizone | 1 | 2008 | 1 | 0.080 |
Why?
|
| Ditiocarb | 1 | 2008 | 3 | 0.080 |
Why?
|
| Mice, Inbred Strains | 1 | 2009 | 189 | 0.080 |
Why?
|
| Transplantation Conditioning | 1 | 2009 | 102 | 0.080 |
Why?
|
| Tooth Movement Techniques | 1 | 2008 | 1 | 0.080 |
Why?
|
| Chelating Agents | 1 | 2008 | 50 | 0.080 |
Why?
|
| Catalepsy | 1 | 2008 | 3 | 0.070 |
Why?
|
| Ischemia | 1 | 2010 | 203 | 0.070 |
Why?
|
| Myocardium | 1 | 2010 | 273 | 0.070 |
Why?
|
| Autonomic Nervous System | 1 | 2008 | 36 | 0.070 |
Why?
|
| Body Weight | 1 | 2009 | 377 | 0.070 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2008 | 48 | 0.070 |
Why?
|
| Tissue Survival | 1 | 2007 | 5 | 0.070 |
Why?
|
| Receptor, Cannabinoid, CB2 | 1 | 2007 | 10 | 0.070 |
Why?
|
| Guanethidine | 1 | 2007 | 3 | 0.070 |
Why?
|
| Ischemic Preconditioning, Myocardial | 1 | 2007 | 23 | 0.070 |
Why?
|
| Heart Diseases | 1 | 2010 | 215 | 0.070 |
Why?
|
| Nitroglycerin | 1 | 2007 | 12 | 0.070 |
Why?
|
| Phenylephrine | 4 | 2008 | 18 | 0.070 |
Why?
|
| Atropine | 1 | 2007 | 13 | 0.070 |
Why?
|
| Streptozocin | 1 | 2007 | 22 | 0.070 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2007 | 19 | 0.070 |
Why?
|
| Cyclosporine | 1 | 2007 | 77 | 0.070 |
Why?
|
| Serotonin | 1 | 2007 | 60 | 0.070 |
Why?
|
| Estrous Cycle | 1 | 2007 | 12 | 0.070 |
Why?
|
| Narcotics | 1 | 2007 | 54 | 0.070 |
Why?
|
| Skin | 1 | 2010 | 377 | 0.070 |
Why?
|
| Superoxide Dismutase | 2 | 2024 | 227 | 0.070 |
Why?
|
| Liver Cirrhosis, Experimental | 1 | 2006 | 6 | 0.070 |
Why?
|
| Long QT Syndrome | 1 | 2006 | 31 | 0.070 |
Why?
|
| Pentoxifylline | 1 | 2006 | 8 | 0.060 |
Why?
|
| Muscle Contraction | 1 | 2007 | 202 | 0.060 |
Why?
|
| Myocardial Contraction | 1 | 2006 | 88 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2006 | 609 | 0.060 |
Why?
|
| Bile Ducts | 3 | 2010 | 25 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2007 | 1107 | 0.060 |
Why?
|
| Glatiramer Acetate | 1 | 2024 | 7 | 0.060 |
Why?
|
| Visceral Pain | 1 | 2024 | 1 | 0.060 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2024 | 12 | 0.050 |
Why?
|
| Inflammation | 2 | 2021 | 1136 | 0.050 |
Why?
|
| Plant Preparations | 1 | 2024 | 16 | 0.050 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 1537 | 0.050 |
Why?
|
| Kynurenine | 1 | 2023 | 7 | 0.050 |
Why?
|
| Anxiety | 1 | 2007 | 421 | 0.050 |
Why?
|
| Orexin Receptor Antagonists | 1 | 2023 | 2 | 0.050 |
Why?
|
| Orexin Receptors | 1 | 2023 | 3 | 0.050 |
Why?
|
| Orexins | 1 | 2023 | 6 | 0.050 |
Why?
|
| Random Allocation | 3 | 2008 | 197 | 0.050 |
Why?
|
| Interleukin-10 | 1 | 2024 | 159 | 0.050 |
Why?
|
| Progesterone | 3 | 2008 | 162 | 0.050 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2023 | 87 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2013 | 5554 | 0.050 |
Why?
|
| Adolescent | 1 | 2013 | 6145 | 0.050 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2022 | 47 | 0.050 |
Why?
|
| Benzamides | 1 | 2022 | 65 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 299 | 0.050 |
Why?
|
| Sciatic Nerve | 1 | 2021 | 26 | 0.050 |
Why?
|
| Diastole | 1 | 2021 | 92 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2022 | 271 | 0.040 |
Why?
|
| Serotonin Antagonists | 2 | 2011 | 32 | 0.040 |
Why?
|
| Sildenafil Citrate | 2 | 2011 | 14 | 0.040 |
Why?
|
| Brain | 1 | 2009 | 1546 | 0.040 |
Why?
|
| Purines | 2 | 2011 | 42 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2021 | 319 | 0.040 |
Why?
|
| Sleep | 1 | 2023 | 225 | 0.040 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2012 | 31 | 0.040 |
Why?
|
| Cytokines | 1 | 2024 | 933 | 0.040 |
Why?
|
| Heart Ventricles | 1 | 2021 | 260 | 0.040 |
Why?
|
| Ventricular Function, Left | 1 | 2021 | 267 | 0.040 |
Why?
|
| Ligation | 2 | 2010 | 37 | 0.040 |
Why?
|
| Receptors, Cannabinoid | 1 | 2018 | 7 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2020 | 282 | 0.040 |
Why?
|
| Microglia | 1 | 2021 | 237 | 0.040 |
Why?
|
| Echocardiography | 1 | 2021 | 498 | 0.040 |
Why?
|
| Excitatory Amino Acid Agents | 1 | 2017 | 5 | 0.040 |
Why?
|
| Magnesium Sulfate | 1 | 2017 | 9 | 0.040 |
Why?
|
| N-Methylaspartate | 1 | 2017 | 16 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 2 | 2008 | 70 | 0.030 |
Why?
|
| Models, Biological | 1 | 2022 | 1177 | 0.030 |
Why?
|
| Diazoxide | 1 | 2016 | 4 | 0.030 |
Why?
|
| Drug Administration Routes | 1 | 2016 | 21 | 0.030 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2016 | 75 | 0.030 |
Why?
|
| Immobilization | 1 | 2015 | 13 | 0.030 |
Why?
|
| Reaction Time | 1 | 2016 | 124 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 463 | 0.030 |
Why?
|
| Protective Agents | 1 | 2012 | 12 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2012 | 317 | 0.020 |
Why?
|
| Biguanides | 1 | 2011 | 1 | 0.020 |
Why?
|
| Yohimbine | 1 | 2011 | 9 | 0.020 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2011 | 13 | 0.020 |
Why?
|
| Indoles | 1 | 2011 | 110 | 0.020 |
Why?
|
| Indazoles | 1 | 2010 | 13 | 0.020 |
Why?
|
| Catalase | 1 | 2010 | 24 | 0.020 |
Why?
|
| Glutathione Peroxidase | 1 | 2010 | 28 | 0.020 |
Why?
|
| Lipid Peroxidation | 1 | 2010 | 65 | 0.020 |
Why?
|
| Granisetron | 1 | 2009 | 13 | 0.020 |
Why?
|
| Kidney | 1 | 2012 | 444 | 0.020 |
Why?
|
| Animals, Inbred Strains | 1 | 2009 | 3 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2008 | 7 | 0.020 |
Why?
|
| Dental Alloys | 1 | 2008 | 1 | 0.020 |
Why?
|
| Dental Cementum | 1 | 2008 | 1 | 0.020 |
Why?
|
| Orthodontic Wires | 1 | 2008 | 1 | 0.020 |
Why?
|
| Root Resorption | 1 | 2008 | 1 | 0.020 |
Why?
|
| Dentin | 1 | 2008 | 4 | 0.020 |
Why?
|
| Mandible | 1 | 2008 | 9 | 0.020 |
Why?
|
| Epilepsy, Generalized | 1 | 2008 | 5 | 0.020 |
Why?
|
| Molar | 1 | 2008 | 4 | 0.020 |
Why?
|
| Epilepsy, Tonic-Clonic | 1 | 2008 | 8 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2008 | 47 | 0.020 |
Why?
|
| Skin Transplantation | 1 | 2009 | 156 | 0.020 |
Why?
|
| Benzoxazines | 1 | 2008 | 11 | 0.020 |
Why?
|
| Osteoclasts | 1 | 2008 | 48 | 0.020 |
Why?
|
| Naphthalenes | 1 | 2008 | 19 | 0.020 |
Why?
|
| Naloxone | 1 | 2008 | 60 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2008 | 76 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 212 | 0.020 |
Why?
|
| Testosterone | 1 | 2008 | 119 | 0.020 |
Why?
|
| Mesenteric Arteries | 1 | 2007 | 10 | 0.020 |
Why?
|
| United States | 1 | 2021 | 7696 | 0.020 |
Why?
|
| Graft Survival | 1 | 2009 | 290 | 0.020 |
Why?
|
| Titanium | 1 | 2008 | 59 | 0.020 |
Why?
|
| Morpholines | 1 | 2008 | 89 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2008 | 111 | 0.020 |
Why?
|
| Bone Density | 1 | 2008 | 134 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2008 | 130 | 0.020 |
Why?
|
| Nickel | 1 | 2008 | 66 | 0.020 |
Why?
|
| Hypotension | 1 | 2007 | 50 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 542 | 0.020 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2008 | 122 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2008 | 202 | 0.020 |
Why?
|
| Maze Learning | 1 | 2007 | 52 | 0.020 |
Why?
|
| Epinephrine | 1 | 2006 | 44 | 0.020 |
Why?
|
| Coronary Vessels | 1 | 2007 | 118 | 0.020 |
Why?
|
| Electrophysiology | 1 | 2006 | 89 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2008 | 339 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2007 | 149 | 0.020 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2006 | 32 | 0.020 |
Why?
|
| Isoproterenol | 1 | 2006 | 36 | 0.020 |
Why?
|
| Papillary Muscles | 1 | 2006 | 14 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2006 | 22 | 0.020 |
Why?
|
| Weight Loss | 1 | 2008 | 272 | 0.020 |
Why?
|
| Hypoxia | 1 | 2006 | 113 | 0.010 |
Why?
|
| Heart Rate | 1 | 2006 | 319 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2006 | 513 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2006 | 548 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2007 | 909 | 0.010 |
Why?
|
| Risk Factors | 1 | 2006 | 5287 | 0.010 |
Why?
|